- Lobbying
- alkermes
Lobbying Arrangements Results for 'Alkermes'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Opioid addiction and treatment issues |
Alkermes Pharmaceuticals Corporation
|
ARTEMIS STRATEGIES | |||
Details Discussion on addiction, recovery and related issues to dependence on alcohol and opiates. |
Alkermes, Inc.
|
DA VINCI GROUP | |||
Details S. 264 The Excellence in Mental Health Act," all provisions. S. 689 The Mental Health Awareness and Improvement Act, all provisions. |
Alkermes, Inc.
|
GUIDE CONSULTING SERVICES, INC. | |||
Details Opioid Crisis |
Alkermes, Inc
|
Prime Policy Group | |||
Details Implementation of Comprehensive Addiction and Recovery Act of 2016 (P.L.114-198) and 21st Century Cures Act (P.L.114-255); issues related to opioid addiction and treatment. |
Alkermes, Inc.
|
Rampy Northrup LLC | |||
Details Regulatory and legislative issues impacting Alkermes. Appropriations. |
Alkermes, Inc.
|
Hannegan Landau Poersch & Rosenbaum Advocacy, LLC | |||
Details FY 24 Appropriations (LHHS (S. 2624, HR 5894), CJS (S. 2321, HR 5893), Interior (HR 4821, S. 2605), MilCon (HR 4366, S. 2127)) regarding Residential Substance Abuse Treatment program, Mentally Ill... |
Alkermes, Inc.
|
TEAM HALLAHAN LLC | |||
Details Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to the reauthorization of th... |
Alkermes, Inc.
|
THE MCMANUS GROUP | |||
Details Mental health and substance abuse issues, including the Comprehensive Addiction and Recovery Act implementation (P.L. 114-198)and Labor, HHS and Commerce, Justice, Science appropriations bill |
Alkermes, Inc.
|
Ernst & Young LLP (Washington Council Ernst & Young) | |||
Details Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Inflation Reduction Act of 2022 implementation Medicaid Drug Rebate Program proposed rule ... |
Alkermes, Inc.
|
in-house lobbying | |||
Details Appropriations for the Comprehensive Addiction and Recovery Act and other resources to treat substance use disorders within the FY2017 and FY2018 House and Senate Commerce-Justice-Science Appropria... |
Alkermes, Inc.
|
Brimley Group Inc. | |||
Details Medicare and Medicaid implementation, Food and Drug regulation, Drug Enforcement Administration and Controlled Substances Act. |
Alkermes
|
East End Group, LLC | |||
Details increasing acceptance of medication assisted therapy in treating abuse of alcohol and opioid dependence |
Alkermes, Inc.
|
STANTON PARK GROUP | |||
Details We will advocate for bills and policies that support treatment for alcohol and opiod dependency. We will advocate for bills and policies that support treatment for alcohol and opiod dependency in t... |
Alkermes, Inc.
|
COVINGTON & BURLING LLP | |||
Details Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program Proposed Rule (CMS-2434-P) -- and operational and patient access challenges w... |
Alkermes, Inc.
|
SPLITOAK STRATEGIES LLC | |||
Details All provisions related to Medicare's Six Protected Classes policy in Medicare Part D |
Partnership for Part D Access (Informal Coalition)
|
in-house lobbying | |||
Details Policies to address the treatment of opioid/alcohol/drug addiction and mental health issues. |
Alkermes, Inc.
|
FEDERAL STREET STRATEGIES, LLC | |||
Details Implementation of the Comprehensive Addiction and Recovery Act of 2016, P.L.114-198. Issues related to the opioid and mental illness epidemic, Commerce, State, Justice, and Labor, Health and Human... |
Alkermes, Inc.
|
Thorn Run Partners | |||
Details Public Law 110-343, Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 Mental health and addiction parity. Add to #17 below: National Institute of Drug Abuse (... |
Alkermes
|
CAPITOL DECISIONS, INC. | |||
Details Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically |
Alkermes, Inc.
Biopharmaceutical company |
BGR Government Affairs | |||
Details Provide guidance and strategic counsel with regard to DEA scheduling of FDA approved products. |
DEA Scheduling Coalition (Informal Coalition)
|
BGR Government Affairs | |||
Details Prescription drug pricing. Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. |
Alkermes, Inc.
|
Todd Strategy Group | |||
Details Issues related to legislation and policies that support treatment for alcohol and opioid dependency at SAMSHA, VA and DOJ |
Alkermes, Inc.
|
S-3 Group | |||
Details Advance the use of and access to FDA-approved medications to treat addiction and mental illness in criminal justice and public health settings; pharmaceutical supply chain issues; drug pricing. Imp... |
Alkermes, Inc.
|
Crossroads Strategies, LLC |